Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3984 - Primary prevention of nausea and vomiting induced by moderately emetogenic chemotherapies: findings from the French CONVINCE-ME survey


10 Sep 2017


Poster display session


Supportive Care and Symptom Management


Florian Scotté


Annals of Oncology (2017) 28 (suppl_5): v543-v567. 10.1093/annonc/mdx388


F. Scotté1, R. Chevrier2, H. Bertucat3

Author affiliations

  • 1 Medical Oncology And Supportive Care Unit, Foch Hospital, 92 - Suresnes/FR
  • 2 Pharmacy Department, Centre Jean Perrin, 63000 - Clermont-Ferrand/FR
  • 3 Pharmacy Department, Centre Jacques Lacarin, 03000 - Vichy/FR


Abstract 3984


Despite the considerable progress achieved in the last 30 years vomiting and especially nausea continue to be two of the most distressing side-effects of cancer chemotherapy. The objective of this survey was to assess the compliance of anti-emesis prescriptions with the ESMO 2016 and French AFSOS 2013 guidelines (French speaking association for supportive care in cancer), in primary prophylaxis of moderately emetogenic chemotherapies (MEC) as defined by ESMO guidelines.


Between February and November 2016, 35 pharmacists and 41 nurses from 35 French centers specialized in cancer treatment completed a 13-item questionnaire drawn up by a scientific committee about their anti-emesis practices. Concurrently, the nurses at each center recorded prospectively treatments prescribed to 10 to 20 patients starting the first cycle of MEC.


Data were gathered on 448 patients with gastrointestinal cancers and 166 with lung cancers; 29% and 47% of all patients were treated with carboplatin or oxaliplatin respectively. The most frequent CINV preventive treatments for the acute phase were the combination of 5HT3 antagonist + corticoid (52% of patients) and the combination of 5HT3 antagonist + corticoid + anti-NK1 (33%). For the delayed phase, 5HT3 antagonist only (23%), anti-NK1 only (17%) and the combination of 5HT3 antagonist + anti-NK1 (17%) were the most prescribed treatment. Overall, 49% and 33% of patients in the acute phase and 10% and 17% in the delayed phase were treated in compliance the ESMO and AFSOS guidelines respectively.


The CONVINCE-ME survey shows inadequate use of existing recommendations at specialized centers and highlights the need for improved understanding and guideline application.

Clinical trial identification

Legal entity responsible for the study

Florian Scotté




F. Scotté: Roche, Vifor, MSD, Teva, Norgine, Prostrakan, Leo pharma, Janssen, Hospira, Boehringer, Sanofi, Amgen, Pierre Fabre Oncologie, Tesaro. H. Bertucat: MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.